G&E Herbal Biotechnology (4911) reported revenue of NT$11.6 million for Oct 2026, -50.7% year on year and +1.4% from the previous month. Revenue for Jan–Oct 2026 was NT$112.6 million (-57.3% year on year).
In Oct 2026, it ranked No. 133 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$11.6 million | -50.7% | +1.4% |
| Sep 2026 | NT$11.4 million | -56.0% | -1.1% |
| Aug 2026 | NT$11.6 million | -55.3% | +2.4% |
| Jul 2026 | NT$11.3 million | -59.5% | -2.3% |
| Jun 2026 | NT$11.6 million | -57.6% | -0.3% |
| May 2026 | NT$11.6 million | -56.9% | +2.5% |
| Apr 2026 | NT$11.3 million | -56.4% | +6.3% |
| Mar 2026 | NT$10.6 million | -59.8% | -2.0% |
| Feb 2026 | NT$10.8 million | -58.7% | +1.1% |
| Jan 2026 | NT$10.7 million | -60.9% | -53.0% |
| Dec 2025 | NT$22.8 million | -6.5% | +0.2% |
| Nov 2025 | NT$22.8 million | -4.3% | -3.2% |
| Oct 2025 | NT$23.6 million | -0.2% | -9.5% |
| Sep 2025 | NT$26 million | +12.0% | +0.5% |
| Aug 2025 | NT$25.9 million | +30.4% | -7.1% |
| Jul 2025 | NT$27.9 million | +45.5% | +2.3% |
| Jun 2025 | NT$27.3 million | +34.0% | +1.5% |
| May 2025 | NT$26.9 million | +33.7% | +3.6% |
| Apr 2025 | NT$25.9 million | +35.6% | -2.1% |
| Mar 2025 | NT$26.5 million | +36.1% | +0.8% |
| Feb 2025 | NT$26.2 million | +49.0% | -4.3% |
| Jan 2025 | NT$27.4 million | +49.6% | +12.3% |
| Dec 2024 | NT$24.4 million | +34.3% | +2.5% |
| Nov 2024 | NT$23.8 million | +51.9% | +0.9% |
| Oct 2024 | NT$23.6 million | +57.4% | +1.6% |
Jan–Oct 2026 cumulative: NT$112.6 million (-57.3% YoY)
Other Biotech & Medical companies
Compare with peers: G&E Herbal Biotechnology vs PEC / G&E Herbal Biotechnology vs Lotus Pharm / G&E Herbal Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
公司行銷團隊建置中
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16